FDA Approves PTSD Device; GLP-1s for ADHD? Probiotics and Geriatric Depression

The FDA cleared Wave Neuroscience’s biomarker-guided neuromodulation system (MeRT) to treat post-traumatic stress disorder (PTSD), the company announced.

Gastrointestinal interoception was disrupted across multiple domains in a study of weight-restored women with anorexia nervosa, with several interoceptive markers tied to relapse risk. (JAMA Psychiatry)

Social media users shared anecdotal reports suggesting GLP-1 drugs may ease symptoms of attention deficit-hyperactivity disorder (ADHD). (New York Post)

Meanwhile, claims data indicated that psychiatrists prescribed roughly 6% of all GLP-1 agents for privately insured U.S. patients from 2018 to 2023. (Journal of Clinical Psychiatry)

A systematic review and meta-analysis showed that psychological and psychosocial interventions had small-to-medium effect sizes on reducing auditory hallucinations in people with schizophrenia spectrum disorders. (JAMA Psychiatry)

Dads can have postpartum depression, too. (Axios)

At-home low-field magnetic stimulation failed to outperform sham on clinician-rated depression in patients with bipolar depression, a randomized study in China found. (Journal of Affective Disorders)

Adding probiotic supplementation to standard care yielded modest improvements in depressive and anxiety symptoms compared with placebo, a trial of adults with geriatric depression showed. (Journal of the American Geriatrics Society)

Psychosis was tied to lower subcortical iron-sensitive MRI values primarily in the substantia nigra, a meta-analysis showed. (American Journal of Psychiatry)

Neumora Therapeutics scrapped development of its investigational depression drug navacaprant after it failed a pair of clinical trials.

An Alzheimer’s disease specialist revealed how she missed early signs of the condition in her father. (STAT)

Please enable JavaScript to view the comments powered by Disqus.